On Monday, H.C. Wainwright reaffirmed a Buy rating with a $10.00 price target on shares of Lexaria Bioscience (NASDAQ:), representing significant upside from the current price of $2.23. According to InvestingPro data, analyst targets for LEXX range from $8 to $12, with the stock showing impressive momentum through a 72.87% return over the past year. […]

On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of Vivani Medical (TASE:), Inc. (NASDAQ: VANI), with a price target of $3.00. Currently trading at $1.18, the stock shows significant upside potential, with analyst targets ranging from $3.00 to $8.00. According to InvestingPro data, the stock has experienced volatility, declining 10.61% in the past

On Monday, H.C. Wainwright began coverage on Sanara MedTech Inc. (NASDAQ: SMTI) with a Buy rating and set a price target of $50.00 per share, representing nearly 50% upside from the current price of $33.68. The firm’s analyst highlighted the company’s focus on developing and commercializing medical technology aimed at improving clinical outcomes in surgical

On Monday, H.C. Wainwright upgraded Aclaris Therapeutics (NASDAQ:) from Neutral to Buy, setting a price target of $20.00. The stock, currently trading at $2.72, has shown remarkable resilience with a 136% gain over the past six months, despite a recent 10% pullback last week. According to InvestingPro data, analyst targets range from $5 to $13,

On Monday, H.C. Wainwright adjusted its price target for SoundHound AI Inc. (NASDAQ: NASDAQ:), raising it significantly to $26.00, up from the previous $8.00. The firm has maintained its Buy rating on the stock. The upgraded target follows a notable surge in the company’s share price, which has climbed 187.7% since the third-quarter results were

On Monday, UBS revised its price target for Aspeed Technology Inc (5274:TT), a company listed on the Taiwan Stock Exchange, reducing it to NT$3,800 from the previous NT$4,300. This adjustment comes with a maintained Neutral rating on the stock. The revision was prompted by concerns over a potential slowdown in the shipment of Baseboard Management

On Monday, RBC Capital Markets maintained its Sector Perform rating for Uniti Group (NASDAQ:) but increased the stock’s price target to $6.00, up from the previous $5.00. The adjustment follows Uniti Group’s third quarter financial results, which aligned with expectations, and the company’s updated guidance that suggests an increase in non-recurring revenue and a slight

On Monday, Omeros (NASDAQ:) Corporation (NASDAQ:OMER) received a positive outlook from D. Boral (OTC:) Capital, as the firm initiated coverage on the biopharmaceutical company’s stock with a Buy rating and a price target of $36.00. The stock, currently trading at $10.31, has shown remarkable momentum with a 215% return year-to-date and a 35% surge in

On Monday, Ionis Pharmaceuticals (NASDAQ:), a $5.7 billion market cap biotech company, maintained its Overweight rating by Piper Sandler following the U.S. Food and Drug Administration’s (FDA) approval of olezarsen (TRYNGOLZA) for adults with familial chylomicronemia syndrome (FCS). According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 8.91x,

On Monday, Truist Securities adjusted its price target for Vertex Pharmaceuticals (NASDAQ:) Incorporated (NASDAQ:VRTX), a prominent biotechnology company with a market capitalization of $101 billion. The stock has experienced significant pressure, falling over 15% in the past week. The firm’s analyst lowered the target to $460 from the previous $550 while maintaining a Buy rating